Ildiko Lingvay (I Lingvay)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 92

Top Topics

Randomized Controlled Trial

Diabetic Retinopathy

Top Venues

Diabetes, obesity & metabolism

Nature medicine

Obesity (Silver Spring, Md.)

This page only lists publications with an associated author ORCID identifier.

Publications

Helen Martina Colhoun, Ildiko Lingvay, Paul M Brown, John Deanfield, Kirstine Brown-Frandsen, Steven E Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John P H Wilding, Johannes F E Mann, Katherine R Tuttle, Thomas Idorn, Naveen Rathor, A Michael Lincoff
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature medicine 30 (7) (2024)
Ildiko Lingvay, John Deanfield, Steven E Kahn, Peter E Weeke, Hermann Toplak, Benjamin M Scirica, Lars Ryden, Naveen Rathor, Jorge Plutzky, Cristobal Morales, A Michael Lincoff, Michael Lehrke, Ole Kleist Jeppesen, Grzegorz Gajos, Helen Martina Colhoun, Bertrand Cariou, Donna H Ryan, null null
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes care 47 (8) (2024)
Julio Rosenstock, Harpreet S Bajaj, Ildiko Lingvay, Simon R Heller
Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review. BMJ open diabetes research & care 12 (3) (2024)
Ildiko Lingvay, John Deanfield, Steven E Kahn, Peter E Weeke, Hermann Toplak, Benjamin M Scirica, Lars Ryden, Naveen Rathor, Jorge Plutzky, Cristobal Morales, A Michael Lincoff, Michael Lehrke, Ole Kleist Jeppesen, Grzegorz Gajos, Helen Martina Colhoun, Bertrand Cariou, Donna H Ryan, null null
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes care 47 (8) (2024)
Helen Martina Colhoun, Ildiko Lingvay, Paul M Brown, John Deanfield, Kirstine Brown-Frandsen, Steven E Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John P H Wilding, Johannes F E Mann, Katherine R Tuttle, Thomas Idorn, Naveen Rathor, A Michael Lincoff
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature medicine 30 (7) (2024)
Julio Rosenstock, Harpreet S Bajaj, Ildiko Lingvay, Simon R Heller
Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review. BMJ open diabetes research & care 12 (3) (2024)
Paola Lockhart Pastor, Amin Amin, Daniel Galvan, Ofelia Negrete Vasquez, Jaime P Almandoz, Ildiko Lingvay
Approach to weight management in patients with advanced chronic kidney disease in a real-life clinical setting. Obesity science & practice 10 (3) (2024)
Steven E Kahn, John E Deanfield, Ole Kleist Jeppesen, Scott S Emerson, Trine Welløv Boesgaard, Helen M Colhoun, Robert F Kushner, Ildiko Lingvay, Bartolome Burguera, Grzegorz Gajos, Deborah Bade Horn, Irene M Hramiak, Ania M Jastreboff, Alexander Kokkinos, Michael Maeng, Ana Laura S A Matos, Francisco J Tinahones, A Michael Lincoff, Donna H Ryan, null null
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes care (2024)
Julio Rosenstock, Harpreet S Bajaj, Ildiko Lingvay, Simon R Heller
Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review. BMJ open diabetes research & care 12 (3) (2024)
Donna H Ryan, Ildiko Lingvay, John Deanfield, Steven E Kahn, Eric Barros, Bartolome Burguera, Helen Martina Colhoun, Cintia Cercato, Dror Dicker, Deborah B Horn, G Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A Michael Lincoff, Sebastian M Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P van Beek, John P H Wilding, Robert F Kushner
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine (2024)
Donna H Ryan, Ildiko Lingvay, John Deanfield, Steven E Kahn, Eric Barros, Bartolome Burguera, Helen Martina Colhoun, Cintia Cercato, Dror Dicker, Deborah B Horn, G Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A Michael Lincoff, Sebastian M Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P van Beek, John P H Wilding, Robert F Kushner
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine (2024)
Ildiko Lingvay, John Deanfield, Steven E Kahn, Peter E Weeke, Hermann Toplak, Benjamin M Scirica, Lars Ryden, Naveen Rathor, Jorge Plutzky, Cristobal Morales, A Michael Lincoff, Michael Lehrke, Ole Kleist Jeppesen, Grzegorz Gajos, Helen Martina Colhoun, Bertrand Cariou, Donna H Ryan, null null
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes care (2024)
Steven E Kahn, John E Deanfield, Ole Kleist Jeppesen, Scott S Emerson, Trine Welløv Boesgaard, Helen M Colhoun, Robert F Kushner, Ildiko Lingvay, Bartolome Burguera, Grzegorz Gajos, Deborah Bade Horn, Irene M Hramiak, Ania M Jastreboff, Alexander Kokkinos, Michael Maeng, Ana Laura S A Matos, Francisco J Tinahones, A Michael Lincoff, Donna H Ryan, null null
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes care 47 (8) (2024)
Donna H Ryan, Ildiko Lingvay, John Deanfield, Steven E Kahn, Eric Barros, Bartolome Burguera, Helen Martina Colhoun, Cintia Cercato, Dror Dicker, Deborah B Horn, G Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A Michael Lincoff, Sebastian M Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P van Beek, John P H Wilding, Robert F Kushner
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine (2024)
Donna H Ryan, Ildiko Lingvay, John Deanfield, Steven E Kahn, Eric Barros, Bartolome Burguera, Helen Martina Colhoun, Cintia Cercato, Dror Dicker, Deborah B Horn, G Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A Michael Lincoff, Sebastian M Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P van Beek, John P H Wilding, Robert F Kushner
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine 30 (7) (2024)
Donna H Ryan, Ildiko Lingvay, John Deanfield, Steven E Kahn, Eric Barros, Bartolome Burguera, Helen Martina Colhoun, Cintia Cercato, Dror Dicker, Deborah B Horn, G Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A Michael Lincoff, Sebastian M Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P van Beek, John P H Wilding, Robert F Kushner
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine (2024)
Julio Rosenstock, Harpreet S Bajaj, Ildiko Lingvay, Simon R Heller
Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review. BMJ open diabetes research & care 12 (3) (2024)
Manasi Tannu, Lisa Kaltenbach, Neha J Pagidipati, Darren K McGuire, Vanita R Aroda, Pradipta R Ray, Nitin Kondamudi, Hussein R Al-Khalidi, Renato Deláscio Lopes, Matthew A Cavender, Adam James Nelson, Julienne Kirk, Ildiko Lingvay, Melissa Magwire, Caroline Regina Richardson, Laura E Webb, Monica Leyva, Ambarish Pandey, Alana Washington, Jonathan Pak, Tanya Gaynor, Waqar Khan, Patrick Weston, Christopher B Granger, Jennifer B Green
Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial. Circulation (2024)
Helen Martina Colhoun, Ildiko Lingvay, Paul M Brown, John Deanfield, Kirstine Brown-Frandsen, Steven E Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John P H Wilding, Johannes F E Mann, Katherine R Tuttle, Thomas Idorn, Naveen Rathor, A Michael Lincoff
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature medicine 30 (7) (2024)
Steven E Kahn, John E Deanfield, Ole Kleist Jeppesen, Scott S Emerson, Trine Welløv Boesgaard, Helen M Colhoun, Robert F Kushner, Ildiko Lingvay, Bartolome Burguera, Grzegorz Gajos, Deborah Bade Horn, Irene M Hramiak, Ania M Jastreboff, Alexander Kokkinos, Michael Maeng, Ana Laura S A Matos, Francisco J Tinahones, A Michael Lincoff, Donna H Ryan, null null
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes care 47 (8) (2024)
Helen Martina Colhoun, Ildiko Lingvay, Paul M Brown, John Deanfield, Kirstine Brown-Frandsen, Steven E Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John P H Wilding, Johannes F E Mann, Katherine R Tuttle, Thomas Idorn, Naveen Rathor, A Michael Lincoff
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature medicine (2024)
Paola Lockhart Pastor, Amin Amin, Daniel Galvan, Ofelia Negrete Vasquez, Jaime P Almandoz, Ildiko Lingvay
Approach to weight management in patients with advanced chronic kidney disease in a real-life clinical setting. Obesity science & practice 10 (3) (2024)
Donna H Ryan, Ildiko Lingvay, John Deanfield, Steven E Kahn, Eric Barros, Bartolome Burguera, Helen Martina Colhoun, Cintia Cercato, Dror Dicker, Deborah B Horn, G Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A Michael Lincoff, Sebastian M Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P van Beek, John P H Wilding, Robert F Kushner
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine 30 (7) (2024)
Donna H Ryan, Ildiko Lingvay, John Deanfield, Steven E Kahn, Eric Barros, Bartolome Burguera, Helen Martina Colhoun, Cintia Cercato, Dror Dicker, Deborah B Horn, G Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A Michael Lincoff, Sebastian M Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P van Beek, John P H Wilding, Robert F Kushner
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine 30 (7) (2024)
Helen Martina Colhoun, Ildiko Lingvay, Paul M Brown, John Deanfield, Kirstine Brown-Frandsen, Steven E Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John P H Wilding, Johannes F E Mann, Katherine R Tuttle, Thomas Idorn, Naveen Rathor, A Michael Lincoff
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature medicine 30 (7) (2024)
Steven E Kahn, John E Deanfield, Ole Kleist Jeppesen, Scott S Emerson, Trine Welløv Boesgaard, Helen M Colhoun, Robert F Kushner, Ildiko Lingvay, Bartolome Burguera, Grzegorz Gajos, Deborah Bade Horn, Irene M Hramiak, Ania M Jastreboff, Alexander Kokkinos, Michael Maeng, Ana Laura S A Matos, Francisco J Tinahones, A Michael Lincoff, Donna H Ryan, null null
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes care 47 (8) (2024)
Helen Martina Colhoun, Ildiko Lingvay, Paul M Brown, John Deanfield, Kirstine Brown-Frandsen, Steven E Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John P H Wilding, Johannes F E Mann, Katherine R Tuttle, Thomas Idorn, Naveen Rathor, A Michael Lincoff
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature medicine 30 (7) (2024)
Ildiko Lingvay, John Deanfield, Steven E Kahn, Peter E Weeke, Hermann Toplak, Benjamin M Scirica, Lars Ryden, Naveen Rathor, Jorge Plutzky, Cristobal Morales, A Michael Lincoff, Michael Lehrke, Ole Kleist Jeppesen, Grzegorz Gajos, Helen Martina Colhoun, Bertrand Cariou, Donna H Ryan, null null
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes care 47 (8) (2024)
Donna H Ryan, Ildiko Lingvay, John Deanfield, Steven E Kahn, Eric Barros, Bartolome Burguera, Helen Martina Colhoun, Cintia Cercato, Dror Dicker, Deborah B Horn, G Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A Michael Lincoff, Sebastian M Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P van Beek, John P H Wilding, Robert F Kushner
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine 30 (7) (2024)
Ildiko Lingvay, Vanita R Aroda, Julie Broe Honoré, Anne S Ersbøll, Lise Lotte Nystrup Husemoen, Anders Boeck Jensen, Kasper Sommer Matthiessen, Mikhail Naum Kosiborod
Patterns of new glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes during 2014-2019 from a US database: prescriber and patient characteristics. Journal of diabetes 15 (2) (2023)
Jaime P Almandoz, Ildiko Lingvay
Encouraging but slow progress toward incorporating obesity care into diabetes care. Obesity (Silver Spring, Md.) (2023)
Vanita R Aroda, Juan Pablo Frias, Li-Nong Ji, Elisabeth Niemoeller, My-Liên Nguyên-Pascal, Karl Denkel, Melanie Espinasse, Hailing Guo, SeungJae Baek, JaeDuk Choi, Ildiko Lingvay
Efficacy and Safety of Once-Weekly Efpeglenatide in People with Suboptimally Controlled Type 2 Diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S Randomised Controlled Trials. Diabetes, obesity & metabolism (2023)
Li-Nong Ji, A J Ahmann, Bo Ahrén, M S Capehorn, P Hu, Ildiko Lingvay, W Liu, Helena W Rodbard, Z Shen, C Sorli
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China. Diabetes, obesity & metabolism (2023)
Natia Murvelashvili, Luyu Xie, Jeffrey N Schellinger, M Sunil Mathew, Elisa Morales Marroquin, Ildiko Lingvay, Sarah E Messiah, Jaime P Almandoz
Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring, Md.) (2023)
Ildiko Lingvay, Shubham Agarwal
A revolution in obesity treatment. Nature medicine (2023)
Ildiko Lingvay, Vanita R Aroda, Julie Broe Honoré, Anne S Ersbøll, Lise Lotte Nystrup Husemoen, Anders Boeck Jensen, Kasper Sommer Matthiessen, Mikhail Naum Kosiborod
Patterns of new glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes during 2014-2019 from a US database: prescriber and patient characteristics. Journal of diabetes 15 (2) (2023)
Ildiko Lingvay, Vanita R Aroda, Julie Broe Honoré, Anne S Ersbøll, Lise Lotte Nystrup Husemoen, Anders Boeck Jensen, Kasper Sommer Matthiessen, Mikhail Naum Kosiborod
Patterns of new glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes during 2014-2019 from a US database: prescriber and patient characteristics. Journal of diabetes 15 (2) (2023)
Harpreet S Bajaj, Jens Aberle, Melanie Jane Davies, Anders Meller Donatsky, Marie Frederiksen, Dilek Gogas Yavuz, Amoolya Gowda, Ildiko Lingvay, Bruce W Bode
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial. Annals of internal medicine (2023)
Julio Rosenstock, Stephen C Bain, Amoolya Gowda, Esteban Jódar, Bo Liang, Ildiko Lingvay, Tomoyuki Nishida, Roberto Trevisan, Ofri Mosenzon, null null
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. The New England journal of medicine (2023)
Klara R Klein, Kim K B Clemmensen, Edwin Fong, Søren Olsen, Trine Abrahamsen, Ildiko Lingvay
Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN 6, and PIONEER 6. Diabetes care (2023)
A Michael Lincoff, Kirstine Brown-Frandsen, Helen M Colhoun, John Deanfield, Scott S Emerson, Sille Esbjerg, Søren Hardt-Lindberg, G Kees Hovingh, Steven E Kahn, Robert F Kushner, Ildiko Lingvay, Tugce K Oral, Marie M Michelsen, Jorge Plutzky, Christoffer W Tornøe, Donna H Ryan, null null
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine (2023)
Shubham Agarwal, Ildiko Lingvay
SGLT inhibitors: a serendipitous glycaemic tale. Nature reviews. Endocrinology (2023)
Ildiko Lingvay, Alice Yy Cheng, Joshua A Levine, Elisa Gomez-Valderas, Sheryl E Allen, Kari Ranta, Amelia Torcello Gómez, Vivian T Thieu
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes, obesity & metabolism 25 (4) (2022)
Ahmed A Kolkailah, Ildiko Lingvay, Idit Dobrecky-Mery, Alona Aharonovich, Jens-Peter David, Cecilie Holse, Søren Rasmussen, Darren K McGuire
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial. Diabetes, obesity & metabolism 25 (4) (2022)
John P H Wilding, Rachel L Batterham, Melanie Jane Davies, Luc F Van Gaal, Kristian Kandler, Katerina Konakli, Ildiko Lingvay, Barbara M McGowan, Tugce Kalayci Oral, Julio Rosenstock, Thomas A Wadden, Sean Wharton, Koutaro Yokote, Robert F Kushner, null null
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism 24 (8) (2022)
Ildiko Lingvay, Alice Yy Cheng, Joshua A Levine, Elisa Gomez-Valderas, Sheryl E Allen, Kari Ranta, Amelia Torcello Gómez, Vivian T Thieu
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes, obesity & metabolism (2022)
Ildiko Lingvay, Robert Bauer, James Baker-Knight, Jack Lawson, Richard E Pratley
An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. The Journal of clinical endocrinology and metabolism 107 (5) (2022)
Ahmed A Kolkailah, Ildiko Lingvay, Idit Dobrecky-Mery, Alona Aharonovich, Jens-Peter David, Cecilie Holse, Søren Rasmussen, Darren K McGuire
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial. Diabetes, obesity & metabolism (2022)
Ildiko Lingvay, Alice Yy Cheng, Joshua A Levine, Elisa Gomez-Valderas, Sheryl E Allen, Kari Ranta, Amelia Torcello-Gómez, Vivian T Thieu
Achievement of glycemic targets with weight loss and without hypoglycemia in type 2 diabetes with once-weekly GIP and GLP-1 receptor agonist tirzepatide: a post-hoc analysis of the SURPASS-1 to -5 studies. Diabetes, obesity & metabolism (2022)
Ahmed A Kolkailah, Ildiko Lingvay, Idit Dobrecky-Mery, Alona Aharonovich, Jens-Peter David, Cecilie Holse, Søren Rasmussen, Darren K McGuire
Effects of Once-Weekly Subcutaneous Semaglutide on Coronary Artery Disease Outcomes in Patients with Type 2 Diabetes with or at High Risk for Cardiovascular Disease: Insights from the SUSTAIN-6 Trial. Diabetes, obesity & metabolism (2022)
Ahmed A Kolkailah, Ildiko Lingvay, Idit Dobrecky-Mery, Alona Aharonovich, Jens-Peter David, Cecilie Holse, Søren Rasmussen, Darren K McGuire
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial. Diabetes, obesity & metabolism 25 (4) (2022)
Ahmed A Kolkailah, Ildiko Lingvay, Idit Dobrecky-Mery, Alona Aharonovich, Jens-Peter David, Cecilie Holse, Søren Rasmussen, Darren K McGuire
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial. Diabetes, obesity & metabolism 25 (4) (2022)
Ildiko Lingvay, Alice Yy Cheng, Joshua A Levine, Elisa Gomez-Valderas, Sheryl E Allen, Kari Ranta, Amelia Torcello Gómez, Vivian T Thieu
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes, obesity & metabolism 25 (4) (2022)
Natasha Chidekel Bergmann, Melanie Jane Davies, Ildiko Lingvay, Filip K Krag Knop
Semaglutide for the treatment of overweight and obesity: A review. Diabetes, obesity & metabolism (2022)
Ildiko Lingvay, Kirstine Brown-Frandsen, Helen M Colhoun, John Deanfield, Scott S Emerson, Sille Esbjerg, Søren Hardt-Lindberg, G Kees Hovingh, Steven E Kahn, Robert F Kushner, A Michael Lincoff, Steven P Marso, Tea Monk Fries, Jorge Plutzky, Donna H Ryan, null null
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring, Md.) 31 (1) (2022)
Ildiko Lingvay, Kirstine Brown-Frandsen, Helen M Colhoun, John Deanfield, Scott S Emerson, Sille Esbjerg, Søren Hardt-Lindberg, G Kees Hovingh, Steven E Kahn, Robert F Kushner, A Michael Lincoff, Steven P Marso, Tea Monk Fries, Jorge Plutzky, Donna H Ryan, null null
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring, Md.) 31 (1) (2022)
Athena Philis-Tsimikas, Harpreet S Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David L Russell-Jones, Julio Rosenstock
Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes, obesity & metabolism (2022)
John A Spertus, Mary C Birmingham, Michael Nassif, C V Damaraju, Antonio Abbate, Javed Butler, David E Lanfear, Ildiko Lingvay, Mikhail Naum Kosiborod, James L Januzzi
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature medicine 28 (4) (2022)
Ildiko Lingvay, Kirstine Brown-Frandsen, Helen M Colhoun, John Deanfield, Scott S Emerson, Sille Esbjerg, Søren Hardt-Lindberg, G Kees Hovingh, Steven E Kahn, Robert F Kushner, A Michael Lincoff, Steven P Marso, Tea Monk Fries, Jorge Plutzky, Donna H Ryan, null null
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring, Md.) (2022)
Khary Edwards, Xilong Li, Ildiko Lingvay
Clinical and Safety Outcomes with GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study. The Journal of clinical endocrinology and metabolism (2022)
Ildiko Lingvay, Kirstine Brown-Frandsen, Helen M Colhoun, John Deanfield, Scott S Emerson, Sille Esbjerg, Søren Hardt-Lindberg, G Kees Hovingh, Steven E Kahn, Robert F Kushner, A Michael Lincoff, Steven P Marso, Tea Monk Fries, Jorge Plutzky, Donna H Ryan, null null
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring, Md.) 31 (1) (2022)
Ildiko Lingvay, Kirstine Brown-Frandsen, Helen M Colhoun, John Deanfield, Scott S Emerson, Sille Esbjerg, Søren Hardt-Lindberg, G Kees Hovingh, Steven E Kahn, Robert F Kushner, A Michael Lincoff, Steven P Marso, Tea Monk Fries, Jorge Plutzky, Donna H Ryan, null null
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring, Md.) 31 (1) (2022)
Leigh Perreault, Melanie Davies, Juan Pablo Frias, Peter Nørkjaer Laursen, Ildiko Lingvay, Sriram Machineni, Anette Varbo, John P H Wilding, Signe Olrik Rytter Wallenstein, Carel W le Roux
Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes care 45 (10) (2022)
Ildiko Lingvay, Alice Yy Cheng, Joshua A Levine, Elisa Gomez-Valderas, Sheryl E Allen, Kari Ranta, Amelia Torcello Gómez, Vivian T Thieu
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes, obesity & metabolism 25 (4) (2022)
Ahmed A Kolkailah, Ildiko Lingvay, Idit Dobrecky-Mery, Alona Aharonovich, Jens-Peter David, Cecilie Holse, Søren Rasmussen, Darren K McGuire
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial. Diabetes, obesity & metabolism 25 (4) (2022)
Ahmed A Kolkailah, Ildiko Lingvay, Idit Dobrecky-Mery, Alona Aharonovich, Jens-Peter David, Cecilie Holse, Søren Rasmussen, Darren K McGuire
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial. Diabetes, obesity & metabolism 25 (4) (2022)
Minh-da Le, Yiling Wu, Jarett D Berry, Jeffrey D Browning, James A de Lemos, Ian J Neeland, Ildiko Lingvay
Associations of liver fat content with cardiometabolic phenotypes and outcomes in a multi-ethnic population: Results from the Dallas Heart Study. Diabetes, obesity & metabolism (2022)
Cyrus V Desouza, Andreas R Kirk, Kamal K Mangla, Michael L Wolden, Ildiko Lingvay
Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs). BMJ open diabetes research & care 8 (2) (2021)
Harpreet S Bajaj, Richard M Bergenstal, Andreas Christoffersen, Melanie J Davies, Amoolya Gowda, Joakim Isendahl, Ildiko Lingvay, Peter A Senior, Robert J Silver, Roberto Trevisan, Julio Rosenstock
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Diabetes care 44 (7) (2021)
Ildiko Lingvay, Thomas Hansen, Stanislava Macura, Michel Marre, Michael A Nauck, Raymond de la Rosa, Vincent Woo, Emre Yildirim, John P H Wilding
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ open diabetes research & care 8 (2) (2021)
Sean Wharton, Melanie Jane Davies, Dror Dicker, Ildiko Lingvay, Lawrence A Leiter, Domenica M Rubino, Sue D Pedersen
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate medicine (2021)
Ildiko Lingvay, Michelle Greenberg, Silvina Gallo, Harry Shi, Jie Liu, Ira Gantz
Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy. Diabetes, obesity & metabolism 23 (7) (2021)
Simon R Heller, Ildiko Lingvay, Steven P Marso, Athena Philis-Tsimikas, Thomas R Pieber, Neil R Poulter, Richard E Pratley, Elise Hachmann-Nielsen, Kajsa Kvist, Martin Lange, Alan C Moses, Marie Trock Andresen, John B Buse, null null
Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. Diabetes, obesity & metabolism 22 (12) (2021)
Richard E Pratley, Andrei-Mircea Catarig, Ildiko Lingvay, Adie Viljoen, Abby Paine, Jack Lawson, Barrie Chubb, Anders Gorst-Rasmussen, Nino Miresashvili
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes, obesity & metabolism 23 (11) (2021)
Vanita R Aroda, Mads Faurby, Søren Lophaven, Josh Noone, Michael Lyng Wolden, Ildiko Lingvay
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study. Diabetes, obesity & metabolism 23 (9) (2021)
Sean Wharton, Salvatore Calanna, Melanie Jane Davies, Dror Dicker, Bryan Goldman, Ildiko Lingvay, Lawrence A Leiter, Domenica M Rubino, Mette Thomsen, Thomas A Wadden, Sue D Pedersen
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, obesity & metabolism 24 (1) (2021)
John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Thomas A Wadden, Sean Wharton, Koutaro Yokote, Niels Zeuthen, Robert F Kushner, null null
Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine 384 (11) (2021)
Ildiko Lingvay, John B Buse, Edward Franek, Melissa V Hansen, Mette M Koefoed, Chantal Mathieu, Jeremy Pettus, Karolina Stachlewska, Julio Rosenstock
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Diabetes care 44 (7) (2021)
Simon R Heller, Ildiko Lingvay, Steven P Marso, Athena Philis-Tsimikas, Thomas R Pieber, Neil R Poulter, Richard E Pratley, Elise Hachmann-Nielsen, Kajsa Kvist, Martin Lange, Alan C Moses, Marie Trock Andresen, John B Buse, null null
Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. Diabetes, obesity & metabolism 22 (12) (2020)
Udoka Obinwa, Adriana Pérez, Ildiko Lingvay, Stephen H Mandy, Ethan A Halm, Michael E Bowen
Multilevel Variation in Diabetes Screening Within an Integrated Health System. Diabetes care 43 (5) (2020)
Carlos A Alvarez, Ethan A Halm, Mary Jo V Pugh, Darren K McGuire, Sean Hennessy, Richard T Miller, Ildiko Lingvay, Scott Martin Vouri, Andrew R Zullo, Hui Yang, Matt Chansard, Eric M Mortensen
Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study. Endocrinology, diabetes & metabolism 4 (1) (2020)
Mansoor Husain, Stephen C Bain, Ole K Jeppesen, Ildiko Lingvay, Rasmus Sørrig, Marianne B Treppendahl, Tina Vilsbøll
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes, obesity & metabolism 22 (3) (2020)
Priya Chelliah, Xilong Li, Beverley Adams-Huet, Ildiko Lingvay
Trends in the prevalence of cardiometabolic disease and cardiovascular events by body mass index category in adults from 1999 to 2016. Postgraduate medical journal 96 (1141) (2020)
Marconi Abreu, Anna Tumyan, Ahmed Elhassan, Katherine Peicher, Olivia Papacostea, Perihan Dimachkie, Muhammad S Siddiqui, Laurentiu M Pop, Uma Gunasekaran, Stephen H Mandy, Beverley Adams-Huet, Xilong Li, Ildiko Lingvay
A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. Diabetes, obesity & metabolism 21 (9) (2019)
Maryam Afkarian, Sarit Polsky, Afshin Parsa, Ronnie Aronson, Maria Luiza Caramori, David Z I Cherney, Jill P Crandall, Ian H de Boer, Thomas G Elliott, Andrzej T Galecki, Allison B Goldfine, J Sonya Haw, Irl B Hirsch, Amy B Karger, Ildiko Lingvay, David M Maahs, Janet B McGill, Mark E Molitch, Bruce A Perkins, Pradipta R Ray, Marlon Pragnell, Sylvia E Rosas, Peter Rossing, Peter Senior, Ronald J Sigal, Catherine Spino, Katherine R Tuttle, Guillermo E Umpierrez, Amisha Wallia, Ruth S Weinstock, Chunyi Wu, Michael Mauer, Alessandro Doria, null null
Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. Diabetes care 42 (8) (2019)
Helena W Rodbard, Julio Rosenstock, Luis H Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Østergaard Lindberg, Ildiko Lingvay, Anette Luther Søndergaard, Marianne Bach Treppendahl, Eduard Montanya, null null
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes care 42 (12) (2019)
Tina Vilsbøll, Stephen C Bain, Lawrence Alan Leiter, Ildiko Lingvay, David Matthews, Rafael Simó, Ida Carøe Helmark, Nelun Wijayasinghe, Michael Larsen
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, obesity & metabolism 20 (4) (2018)
Laurentiu M Pop, Andrea Mari, Tong-Jin Zhao, Lori Mitchell, Shawn Burgess, Xilong Li, Beverley Adams-Huet, Ildiko Lingvay
Roux-en-Y gastric bypass compared with equivalent diet restriction: Mechanistic insights into diabetes remission. Diabetes, obesity & metabolism 20 (7) (2018)
Ildiko Lingvay, Cyrus V Desouza, Katarina S Lalic, Ludger Rose, Thomas Hansen, Jeppe Zacho, Thomas R Pieber
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. Diabetes care 41 (9) (2018)
Paul Norwood, Roger Chen, Elmar Jaeckel, Ildiko Lingvay, Henrik Jarlov, Lucine Lehmann, Simon R Heller
Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Diabetes, obesity & metabolism 19 (11) (2017)
Andrew J Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G Holst, Miriam P Annett, Vanita R Aroda
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes care 41 (2) (2017)
Ildiko Lingvay, Stewart Harris, Elmar Jaeckel, Keval Chandarana, Mattis F Ranthe, Esteban Jódar
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. Diabetes, obesity & metabolism 20 (1) (2017)